Andalusia to Cover Pioneering ‘Butterfly Skin’ Treatment for Leo and 44 Others
The Andalusian regional government will fund Vyjuvek, a groundbreaking treatment for dystrophic epidermolysis bullosa (DEB), commonly known as “butterfly skin.” This decision follows a powerful testimony by 12-year-classic Leo García at the European Parliament, which brought attention to the challenges faced by those with this rare genetic condition.
What is Butterfly Skin?
Epidermolysis bullosa dystrophica is a rare inherited disorder causing blistering of the skin and mucous membranes. Blisters often appear at birth in areas like hands, feet, knees, mouth, esophagus, and even the eyes, according to the U.S. National Institutes of Health (NIH).
The NIH reports that these lesions can lead to scarring and skin thinning, along with symptoms like white bumps, deformities in fingers and nails, difficulty eating, vision problems, anemia, and growth delays. Some individuals with DEB have a significantly increased risk of developing squamous cell skin cancer at a young age.
Approximately 10 people per million are affected by this condition, meaning around 500 individuals in Spain currently live with DEB.
Leo’s Story: A Plea for Change
Leo García shared his daily struggles with the European Parliament, describing a painful morning routine and constant fear of injury. “My day starts at seven in the morning, with a very painful dressing. I start the day fighting against the pain,” he explained. Even speaking is tough due to sores in his mouth. He expressed fear of playing and eating, highlighting the limitations imposed by his condition.
Vyjuvek: A Potential Breakthrough
Currently, there is no cure for DEB. Leo’s testimony highlighted the availability of Vyjuvek in other European countries. The treatment utilizes a modified virus to deliver functional copies of the defective gene responsible for the condition. According to the drug’s documentation, this helps the skin heal.
The European Medicines Agency (EMA) recommended Vyjuvek’s approval in February 2025, citing its effectiveness in wound healing and a favorable benefit-risk profile. It was approved for use across the European Union in April 2025, but remains unavailable in Spain.
Leo concluded his address with a poignant plea: “If my skin were yours for just one day, I know you would do everything to change things. Please aid us live without fear.”
Andalusia Steps Up
Juanma Moreno, President of the Junta de Andalucía, announced the government’s commitment to covering the cost of Vyjuvek. He stated that the treatment will be available to Leo and 44 other patients in the region within weeks, through the Andalusian Health Service (SAS).
The medication costs approximately €100,000 per patient per month. Moreno expressed hope that Andalusia’s leadership will encourage other regions to follow suit, potentially lowering the medication’s price.
Pro Tip:
Advocacy and raising awareness, as demonstrated by Leo and his family, can be powerful catalysts for change in accessing rare disease treatments.
FAQ
What is epidermolysis bullosa dystrophica? It’s a rare genetic skin disorder causing blistering and fragility.
What does Vyjuvek do? It delivers a functional gene to help the skin heal.
How much does Vyjuvek cost? Approximately €100,000 per patient per month.
When will the treatment be available in Andalusia? Within a few weeks, according to the regional government.
How many people in Spain have butterfly skin? Around 500 people are estimated to live with the condition.
Did you know? Leo’s testimony in the European Parliament played a crucial role in accelerating access to this life-changing treatment.
Learn more about epidermolysis bullosa from the National Institutes of Health.
Share this article to help raise awareness about butterfly skin and the importance of access to innovative treatments!
